Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cells.

Tuomela J, Sandholm J, Kaakinen M, Patel A, Kauppila JH, Ilvesaro J, Chen D, Harris KW, Graves D, Selander KS.

Breast Cancer Res Treat. 2013 Dec;142(3):477-87. doi: 10.1007/s10549-013-2762-0. Epub 2013 Nov 10.

2.

Estrogen receptor-α and sex steroid hormones regulate Toll-like receptor-9 expression and invasive function in human breast cancer cells.

Sandholm J, Kauppila JH, Pressey C, Tuomela J, Jukkola-Vuorinen A, Vaarala M, Johnson MR, Harris KW, Selander KS.

Breast Cancer Res Treat. 2012 Apr;132(2):411-9. doi: 10.1007/s10549-011-1590-3. Epub 2011 May 24.

PMID:
21607583
3.

Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer.

Tuomela J, Sandholm J, Karihtala P, Ilvesaro J, Vuopala KS, Kauppila JH, Kauppila S, Chen D, Pressey C, Härkönen P, Harris KW, Graves D, Auvinen PK, Soini Y, Jukkola-Vuorinen A, Selander KS.

Breast Cancer Res Treat. 2012 Sep;135(2):481-93. doi: 10.1007/s10549-012-2181-7. Epub 2012 Jul 31.

PMID:
22847512
4.

Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion.

Ilvesaro JM, Merrell MA, Li L, Wakchoure S, Graves D, Brooks S, Rahko E, Jukkola-Vuorinen A, Vuopala KS, Harris KW, Selander KS.

Mol Cancer Res. 2008 Oct;6(10):1534-43. doi: 10.1158/1541-7786.MCR-07-2005.

5.

Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity.

Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW, Selander KS.

Mol Cancer Res. 2006 Jul;4(7):437-47.

6.

Toll-like receptor 9 agonist inhibits ERalpha-mediated transactivation by activating NF-kappaB in breast cancer cell lines.

Qiu J, Wang X, Guo X, Zhao C, Wu X, Zhang Y.

Oncol Rep. 2009 Oct;22(4):935-41.

PMID:
19724876
7.

[Establishment of a bioluminescent MDA-MB-231 cell line for in vivo imaging of human triple-negative breast cancer xenograft].

Wang K, Xie SM, He JJ, Ren Y, Xia HB, Zhang XW.

Nan Fang Yi Ke Da Xue Xue Bao. 2011 Nov;31(11):1812-8. Chinese.

8.

Toll-like receptor 9 in breast cancer.

Sandholm J, Selander KS.

Front Immunol. 2014 Jul 22;5:330. doi: 10.3389/fimmu.2014.00330. eCollection 2014. Review.

9.

Establishment of a bioluminescent MDA-MB-231 cell line for human triple-negative breast cancer research.

Wang K, Xie S, Ren Y, Xia H, Zhang X, He J.

Oncol Rep. 2012 Jun;27(6):1981-9. doi: 10.3892/or.2012.1742. Epub 2012 Mar 22.

PMID:
22446691
10.

Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors.

Berger R, Fiegl H, Goebel G, Obexer P, Ausserlechner M, Doppler W, Hauser-Kronberger C, Reitsamer R, Egle D, Reimer D, Müller-Holzner E, Jones A, Widschwendter M.

Cancer Sci. 2010 Apr;101(4):1059-66. doi: 10.1111/j.1349-7006.2010.01491.x. Epub 2010 Jan 12.

11.

Toll-like receptor 9 ligands enhance mesenchymal stem cell invasion and expression of matrix metalloprotease-13.

Nurmenniemi S, Kuvaja P, Lehtonen S, Tiuraniemi S, Alahuhta I, Mattila RK, Risteli J, Salo T, Selander KS, Nyberg P, Lehenkari P.

Exp Cell Res. 2010 Oct 1;316(16):2676-82. doi: 10.1016/j.yexcr.2010.05.024. Epub 2010 May 27.

PMID:
20553713
12.

Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis.

González-Reyes S, Marín L, González L, González LO, del Casar JM, Lamelas ML, González-Quintana JM, Vizoso FJ.

BMC Cancer. 2010 Dec 3;10:665. doi: 10.1186/1471-2407-10-665.

13.

Toll-like receptor-9 expression is inversely correlated with estrogen receptor status in breast cancer.

Jukkola-Vuorinen A, Rahko E, Vuopala KS, Desmond R, Lehenkari PP, Harris KW, Selander KS.

J Innate Immun. 2009;1(1):59-68. doi: 10.1159/000151602. Epub 2008 Aug 28.

PMID:
20375566
14.

IGF-1 induced HIF-1α-TLR9 cross talk regulates inflammatory responses in glioma.

Sinha S, Koul N, Dixit D, Sharma V, Sen E.

Cell Signal. 2011 Nov;23(11):1869-75. doi: 10.1016/j.cellsig.2011.06.024. Epub 2011 Jul 3.

PMID:
21756999
15.

Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.

Gründker C, Föst C, Fister S, Nolte N, Günthert AR, Emons G.

Breast Cancer Res. 2010;12(4):R49. doi: 10.1186/bcr2606. Epub 2010 Jul 14.

16.

Silencing Toll-like receptor-9 in Pseudomonas aeruginosa keratitis.

Huang X, Barrett RP, McClellan SA, Hazlett LD.

Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4209-16.

PMID:
16249500
17.

Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma.

Brignole C, Marimpietri D, Di Paolo D, Perri P, Morandi F, Pastorino F, Zorzoli A, Pagnan G, Loi M, Caffa I, Erminio G, Haupt R, Gambini C, Pistoia V, Ponzoni M.

Cancer Res. 2010 Dec 1;70(23):9816-26. doi: 10.1158/0008-5472.CAN-10-1251. Epub 2010 Oct 8.

18.

Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors.

Väisänen MR, Väisänen T, Jukkola-Vuorinen A, Vuopala KS, Desmond R, Selander KS, Vaarala MH.

Prostate. 2010 Jun 1;70(8):817-24. doi: 10.1002/pros.21115.

PMID:
20054821
19.

Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro.

Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW, Selander KS.

Prostate. 2007 May 15;67(7):774-81.

PMID:
17373717
20.

Short DNA sequences and bacterial DNA induce esophageal, gastric, and colorectal cancer cell invasion.

Kauppila JH, Karttunen TJ, Saarnio J, Nyberg P, Salo T, Graves DE, Lehenkari PP, Selander KS.

APMIS. 2013 Jun;121(6):511-22. doi: 10.1111/apm.12016. Epub 2012 Oct 22.

PMID:
23082743
Items per page

Supplemental Content

Write to the Help Desk